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fibrinolytic therapy, so there is a fine balance between allowing
sufficient time for fibrinolytic therapy to work and not delaying to
the extent that there is little myocardium to salvage. b) Although
it seems logical that a 60-min ECG protocol would result in
inclusion of lower-risk patients than would a 90-min (or 120-min)
ECG protocol, there is evidence that a 60-min ECG identifies
high-risk patients just as well as an ECG performed at 180 min
(3). The MERLIN trial results support this. The 60-min ECG
identified a population at significantly higher risk of adverse events
than did previous studies (4). In addition, over 40% of patents in
the rescue arm had Thrombolysis In Myocardial Infarction
(TIMI) flow grade 3 in the infarct-related vessel, and therefore
may not have been taken to the catheter laboratory on the basis of
a 90-min ECG. One might expect these patients to be a low-risk
subgroup, but we observed a 36% incidence of the composite
secondary end point at 30 days. This high event rate cannot be
attributed to the procedure itself, because less than one-third of
patients with TIMI flow grade 3 had an immediate angioplasty,
and all of these were technically successful. c) Relying on a later
ECG for the diagnosis of failed fibrinolysis would result in further
delays in the rescue angioplasty process. In particular, we were
concerned that transferred patients could be disadvantaged by a
longer period between the onset of fibrinolytic therapy and the
diagnosis of failed fibrinolysis, given the inevitable further delay
associated with transfer. In the end, 40% of patients in the rescue
arm were transferred, and the time delay was almost 2 h (105 32
min). d) Neither a 60-min nor 90-min ECG addresses the
problem of using paired static ECGs to make a diagnosis of failed
fibrinolysis. This method provides no information on whether
persistent ST-segment elevation on the second ECG is the result
of failure to reperfuse or reperfusion injury, nor does it provide any
information on subsequent stability of the ST segments. None-
theless, it remains the most simple and practical noninvasive test
currently available.
Third, the investigators have missed our remarks on the
presence or absence of ongoing chest pain. We agree that chest
pain should be evaluated following administration of fibrinolytic
therapy, and it is possible that this could reduce the number of
patients who are exposed unnecessarily to a rescue procedure.
However, our large experience of infarct angioplasty, before and
including the MERLIN trial, is that the presence of chest pain is
not a reliable predictor of persistent arterial occlusion and that the
absence of chest pain is a very poor indicator of arterial patency.
This is consistent with the observations of other investigators (5).
It is unclear whether the assessment of symptoms is more useful for
predicting perfusion at the cellular level. We recorded the presence
or absence of chest pain in all MERLIN trial patients at the time
of randomization. In the article discussion, we report that, in the
rescue arm, 53% of those who were pain free at randomization had
inadequate antegrade flow in the infarct-related vessel and 38% of
those in pain at randomization had normal antegrade flow in the
infarct-related vessel.
Furthermore, 43% of rescue-arm patients who were pain free
immediately before the coronary angiogram had inadequate ante-
grade flow in the infarct-related vessel, and 26% of those in pain
immediately before the coronary angiogram had normal antegrade
flow in the infarct-related vessel. Therefore, reliance on the
presence or absence of ongoing symptoms would have resulted in
a large number of incorrect diagnoses and, in particular, a large
number of incorrect diagnoses of successful fibrinolysis.
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Influence of Pretreatment Systolic Blood
Pressure on Benefit From Carvedilol
in Severe Chronic Heart Failure Patients
According to the important report by Rouleau et al. (1) and the
thoughtful accompanying editorial by Cohn (2), one would expect
heart-failure patients with the lowest systolic blood pressure, and
who are at the highest risk because of the severity of heart failure,
to enjoy a higher relative benefit from carvedilol compared to
patients with higher systolic blood pressure. Would the investiga-
tors speculate on why the relative benefit was similar across all
pretreatment systolic blood pressure levels?
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